WebDoctor Encyclopedia

Article

ALK Inhibitors

What are ALK inhibitors?

ALK inhibitors are targeted cancer medicines that block an abnormal protein called ALK (anaplastic lymphoma kinase). They are taken as tablets or capsules, usually every day, and are mainly used for people with lung cancer that carries an ALK gene change, often called ALK-positive lung cancer.

In ALK-positive cancer, a piece of the ALK gene has broken off and joined with another gene. This fusion gene makes a protein that is permanently switched on, constantly telling the cancer cell to grow. ALK inhibitors switch off this signal, which often makes tumours shrink quickly.

ALK-positive lung cancer is uncommon, found in roughly 3-5% of non-small cell lung cancers. It is more often seen in younger people and in people who have never smoked or smoked only lightly. Many people take an ALK inhibitor for several years.

Medicines in this group

Medicine Generation Notes
Crizotinib First The first ALK inhibitor; also blocks ROS1 and MET
Ceritinib Second Now less widely used
Alectinib Second A common first choice; works well in the brain
Brigatinib Second A first-choice option; works well in the brain
Ensartinib Second Approved in some countries
Lorlatinib Third Very active in the brain; also works after other ALK inhibitors

A brief history

In 2007, Japanese researchers discovered the EML4-ALK fusion gene in lung cancer. Crizotinib, a drug already in development for other targets, was quickly tested in people with ALK-positive tumours and showed dramatic responses. It was approved in the United States in 2011, only four years after the discovery. Newer drugs that reach the brain better and overcome resistance followed over the next decade.

1. Key facts at a glance

Feature Details
Type of treatment Targeted therapy (kinase inhibitor)
Main use ALK-positive non-small cell lung cancer
How it is given Tablets or capsules by mouth, once or twice daily
Duration Usually continued for as long as it works
Test needed ALK test on tumour tissue or blood
Main side effects Vary by drug: tiredness, constipation, swelling, weight gain, liver changes, high cholesterol, vision effects

2. How it works

Blocking the growth signal

ALK is a kinase, a protein that passes on signals by adding phosphate groups to other proteins. In ALK-positive cancers, the fusion protein is always active. ALK inhibitors fit into the part of the protein that uses energy (ATP) and stop it from sending signals. Without this signal, many cancer cells stop growing and die.

Reaching the brain

Lung cancer often spreads to the brain, and ALK-positive cancer is no exception. Crizotinib reaches the brain poorly, but newer ALK inhibitors such as alectinib, brigatinib and lorlatinib cross into the brain much better. This means they can shrink brain tumours and help prevent new ones.

Resistance

Over time, most cancers find a way around the drug. Sometimes the ALK gene picks up new mutations that stop the drug from binding. Lorlatinib was designed to overcome many of these mutations. In other cases, the cancer switches to a different growth pathway or changes its cell type.

3. Who it is for

Conditions treated

Condition Role of ALK inhibitors
Non-small cell lung cancer Standard first treatment for advanced ALK-positive cancer
Lung adenocarcinoma The type of lung cancer in which ALK fusions are almost always found
Anaplastic large cell lymphoma (ALCL) Crizotinib for some ALK-positive lymphoma that has come back, mainly in children and young adults
Inflammatory myofibroblastic tumour ALK-positive tumours that cannot be removed with surgery
Neuroblastoma Being studied for tumours with ALK mutations

Testing for ALK

Test What it involves
Immunohistochemistry A stain on the tumour sample shows the ALK protein
FISH A test that shows whether the ALK gene has split
Next-generation sequencing Checks many genes at once, including ALK
Liquid biopsy Looks for tumour DNA in the blood when tissue is not available

International guidelines recommend testing all advanced non-squamous non-small cell lung cancers for ALK and other gene changes before starting treatment.

Early-stage disease

Alectinib is now also used after surgery for some people with early-stage ALK-positive lung cancer, to lower the chance of the cancer coming back. Your team can tell you whether this applies to you.

Choosing a first ALK inhibitor

For most people with newly diagnosed advanced ALK-positive lung cancer, the first treatment is alectinib, brigatinib or lorlatinib. Each is more effective than crizotinib. Lorlatinib appears to keep the cancer under control for longest, especially in the brain, but its side effects on mood, thinking and cholesterol need careful monitoring.

Alectinib and brigatinib tend to cause fewer of these problems. The choice depends on your health, brain involvement, other medicines, local availability and your own preferences, and it is reasonable to ask your specialist to explain the trade-offs.

4. Before treatment

Step Why it is done
Biopsy and gene tests Confirm ALK-positive cancer
CT and brain MRI Show where the cancer is, including the brain
Blood tests Liver, kidney, blood counts, cholesterol and sugar
Heart tracing (ECG) Some ALK inhibitors slow the heart rate or affect heart rhythm
Medicines review Many medicines and some foods interact with ALK inhibitors
Contraception and fertility advice These drugs can harm an unborn baby

Interactions

ALK inhibitors are broken down in the liver, and many other medicines can change their levels. These include some antibiotics, antifungals, anti-seizure medicines and herbal products such as St John’s wort. Grapefruit can also affect some ALK inhibitors. Always check with your pharmacist before starting anything new.

5. What to expect: step by step

Step What happens
1. Start medicine Take tablets or capsules at home as prescribed
2. Early review Usually 2-4 weeks after starting
3. Regular blood tests Especially in the first months
4. Scans Usually every 2-3 months at first
5. Dose changes The dose may be lowered if side effects are troublesome
6. Ongoing treatment Continued for as long as it works and is tolerated

Taking your medicine

Take your medicine at the same time each day, with or without food as advised for your particular drug. Alectinib is taken with food twice a day, while lorlatinib and brigatinib are taken once a day. If you miss a dose, follow the advice on the leaflet or ask your team; do not take two doses together.

6. Side effects and risks

Side effects by medicine

Medicine More typical side effects
Crizotinib Visual flashes or blurring, nausea, diarrhoea, swelling, liver changes
Alectinib Constipation, muscle aches, swelling, weight gain, sun sensitivity, slow heart rate, anaemia
Brigatinib Early breathing problems in the first days, high blood pressure, raised muscle enzymes
Lorlatinib High cholesterol and triglycerides, weight gain, swelling, tingling, changes in mood, memory or speech

Serious but uncommon risks

Risk What to look for
Lung inflammation New or worsening cough, breathlessness or fever
Liver problems Yellow skin or eyes, dark urine
Slow heart rate Dizziness or fainting
Mood and thinking changes Especially with lorlatinib; families may notice first

Managing side effects

Most side effects can be managed by treating the symptom, pausing the medicine briefly or lowering the dose. Lowering the dose does not usually reduce how well the drug works. Cholesterol-lowering medicine is often needed with lorlatinib.

7. Results and outlook

Study Main finding
Crizotinib vs chemotherapy, previously treated cancer Crizotinib held the cancer in check for a median of 7.7 months, against 3.0 months on chemotherapy, and tumours shrank in 65% versus 20% (Shaw et al., 2013)
ALEX trial, alectinib vs crizotinib At 12 months, 68% were free of progression with alectinib versus 49% with crizotinib; brain progression occurred in 12% versus 45% (Peters et al., 2017)
CROWN trial, lorlatinib vs crizotinib At 12 months, 78% were free of progression with lorlatinib versus 39% with crizotinib; most people with measurable brain tumours had them shrink on lorlatinib (Shaw et al., 2020)

Long-term outlook

ALK inhibitors have transformed the outlook for ALK-positive lung cancer. Many people now live for several years with advanced disease while keeping a good quality of life. The newer drugs control the cancer for much longer than crizotinib did, particularly in the brain (Peters et al., 2017; Shaw et al., 2020).

8. Recovery and aftercare

Living with long-term treatment

Tip Why
Use sun protection Some ALK inhibitors cause sun sensitivity
Watch your weight and diet Weight gain and raised cholesterol are common with some drugs
Keep active Helps with tiredness, muscle aches and weight
Tell your team about mood changes These can be managed
Keep all scan appointments Changes are picked up early
Carry a medicines list Important for any other doctor or pharmacist

Children and young people

ALK inhibitors are also used in some children and young people, particularly for ALK-positive anaplastic large cell lymphoma and inflammatory myofibroblastic tumour. In these settings they may be given for a set period rather than indefinitely, and treatment is planned by specialist children’s cancer teams.

When the cancer grows

If the cancer starts to grow, a new biopsy or blood test may look for resistance changes. Options may include switching to another ALK inhibitor, treating a single growing area with targeted radiotherapy while staying on the same drug, chemotherapy, or a clinical trial.

Pregnancy and fertility

ALK-positive lung cancer is often found in younger adults, some of whom are planning a family. ALK inhibitors can harm an unborn baby, so effective contraception is needed during treatment and for some time after stopping. Some ALK inhibitors may make hormonal contraception less effective, so a barrier method may also be recommended. If you would like children in the future, ask for a referral to a fertility specialist before or during treatment.

Emotional wellbeing

Living with a cancer that is controlled but not cured can bring its own challenges. Regular scans can cause anxiety, sometimes called scanxiety, and planning for the future can feel uncertain. Many people find it helpful to connect with others who have ALK-positive lung cancer, through patient groups or online communities. Psychological support is available through most cancer centres.

9. Alternatives

Alternative When it is considered
Chemotherapy After ALK inhibitors stop working
Stereotactic radiosurgery A few brain metastases
Stereotactic body radiotherapy Single growing areas elsewhere in the body
EGFR inhibitors Used instead for lung cancers with EGFR mutations, not ALK fusions
TRK inhibitors Used instead for cancers with NTRK fusions
Immune checkpoint inhibitors Generally less effective in ALK-positive lung cancer

10. Frequently asked questions

Question Answer
Is this chemotherapy? No, it is a targeted therapy
Will I lose my hair? Hair loss is uncommon
How long will I take it? As long as it works and you tolerate it, often years
Can I work and travel? Many people do
Can I take vitamins or herbal remedies? Check first, as some interact
Is ALK-positive cancer inherited? No, the ALK fusion develops in the tumour only
Can I drink alcohol? Small amounts are usually fine, but check, as some drugs affect the liver
Will I need a biopsy again later? Sometimes, to look for resistance changes when the cancer grows
Do these drugs affect driving? Usually not, but avoid driving if you feel dizzy or have vision changes
Can I have vaccines? Most inactivated vaccines are fine; check with your team
Should I have immunotherapy too? Usually not, as it adds side effects without clear benefit

11. Questions to ask your care team

  • Which ALK inhibitor do you recommend, and why?
  • How will we check the brain?
  • What side effects are most likely with this drug?
  • What should I do if I miss a dose?
  • What happens when the drug stops working?
  • Are there clinical trials I could join?

Resources

  1. Peters, S. et al. (2017) ‘Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer’, New England Journal of Medicine, 377(9), pp. 829-838.
  2. Shaw, A.T. et al. (2013) ‘Crizotinib versus chemotherapy in advanced ALK-positive lung cancer’, New England Journal of Medicine, 368(25), pp. 2385-2394.
  3. Shaw, A.T. et al. (2020) ‘First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer’, New England Journal of Medicine, 383(21), pp. 2018-2029.
  4. National Cancer Institute (2026) Non-Small Cell Lung Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq (Accessed: October 2026).
  5. National Cancer Institute (2026) Alectinib. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/alectinib (Accessed: October 2026).
  6. National Cancer Institute (2026) Lorlatinib. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/lorlatinib (Accessed: October 2026).

Prepared by the editorial team, October 2026.